Canadian flagCanadian fulfilment · Free shipping $199+For laboratory research only
My account →Peptide Points →About Peptide Place →

Research Library

GLP-1, GIP & Glucagon Receptors Explained

Published November 2, 2026 · Updated November 8, 2026

Editorial cover for GLP-1, GIP & Glucagon Receptors Explained
Editorial illustration · read the original sources for evidence.

GLP-1, GIP and glucagon receptors are different biological targets involved in metabolic signalling. The familiar comparison is that semaglutide targets GLP-1 receptors, tirzepatide targets GIP and GLP-1 receptors, and retatrutide targets all three. Counting targets helps explain the names, but does not rank clinical results or establish equivalence between materials.

What is a receptor agonist?

A receptor receives a molecular signal. An agonist activates a receptor in a way that can trigger a biological response. A compound’s receptor profile describes part of its pharmacology; it is not a complete description of its behaviour. Exposure, selectivity, signalling characteristics and study context also matter.

A useful way to read a mechanism claim is to translate it into a question: which receptor was examined, in which system, and what response was measured? A receptor assay is different from a controlled study measuring body weight over time. Keeping these levels separate makes the terminology easier to use without making it carry more evidence than it contains.

Compound Common receptor description Reading question
Semaglutide GLP-1 receptor agonist Which population and outcome did the study examine?
Tirzepatide GIP and GLP-1 receptor agonist Was the comparison direct or across separate trials?
Retatrutide GIP, GLP-1 and glucagon receptor agonist Which trial phase, design and endpoints are being cited?

Why the pathways are discussed together

These receptor names appear together because they connect with metabolic regulation. The compounds are often discussed around weight-management research, but body weight is only one possible outcome. Glucose-related measurements, appetite-related questions, body-composition outcomes and safety observations are different pieces of a study.

Avoid reducing the comparison to a slogan such as “one versus two versus three.” That can identify a receptor-targeting distinction while concealing important differences in experimental design. If you want to compare results, use the population, comparator, duration and endpoint alongside the receptor description.

How to read the retatrutide research example

The 2023 phase 2 report by Jastreboff and colleagues describes retatrutide as a triple-hormone-receptor agonist and reports a randomised obesity trial. It is a useful source for understanding how a mechanism description is connected to a particular study. It is not evidence that every retail research vial is the study material.

When reading the paper, separate the primary endpoint from additional analyses and adverse-event reporting. Check the studied population and the timing of measurements. This guide uses that historical trial as an example; it does not claim to be a current development-status or regulatory-status summary.

Why percentages from separate trials can mislead

Different trials can enrol different participants, use different comparators and measure outcomes at different times. Their handling of discontinuation or missing data can differ as well. A larger headline percentage in one study is not automatically proof that its compound outperformed another in a direct comparison.

When a direct comparison exists, read its own design rather than importing results from a different trial. When you only have separate studies, describe that limitation. The three-way comparison keeps the mechanism discussion together, while the Retatrutide research profile focuses on that compound.

Mechanism is separate from a product specification

A product page should identify the supplied compound, package options, current price and available documentation. The receptor mechanism explains a research interest; it does not verify the vial’s identity, amount or lot. Those facts need their own specification and source records.

The Retatrutide listing provides the current catalogue options. Semaglutide and tirzepatide can be discussed as comparison compounds without implying that either is currently offered. Check the live shop for actual availability instead of treating a comparison article as a stock list.

Common questions

Does triple agonist mean three separate peptides in one vial?

No. The term describes receptor activity. It is different from a blend containing several named compounds.

Are these the same research family as MOTS-c?

MOTS-c has a mitochondrial-derived research background. A broad metabolism category does not make its mechanism equivalent to these receptor-targeting compounds.

Does a mechanism description establish a personal outcome?

No. Interpret outcomes through the actual study design, material and population.

Source and further reading

Jastreboff et al., 2023: Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a phase 2 trial. Also see how to read peptide research for an evidence checklist.

Three natural signals, explained first

What is GLP-1?

GLP-1 is a hormone released from the gut in response to food. Its signalling helps coordinate blood-glucose control, including insulin release when glucose is elevated. It also relates to appetite and the movement of food through the stomach. An agonist is a molecule that activates a receptor, the protein that receives a signal.

What is GIP?

GIP is another gut hormone involved in the response to a meal. Like GLP-1, it can support glucose-dependent insulin release. GIP and GLP-1 are called incretins because of this meal-related effect. Their receptors are different targets, so activating one does not automatically reproduce the effects of activating both.

What does glucagon do?

Glucagon helps the liver release glucose, particularly when food is not arriving. Its biology also connects with energy use. This can seem surprising beside medicines associated with lower blood glucose. A multi-receptor molecule combines activities; the overall effect needs to be measured rather than guessed from one hormone’s name.

Why more receptors do not automatically mean a better result

Semaglutide activates GLP-1 receptors. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide is studied as an agonist at GIP, GLP-1 and glucagon receptors. Receptor activity, exposure and trial design all matter. Counting targets does not predict every benefit or unwanted effect.

The original hormone and a designed receptor agonist are also different molecules. A term such as “GLP-3” is not a substitute for identifying retatrutide and its three receptor targets. Our semaglutide, tirzepatide and retatrutide comparison puts those identities side by side.

A direct trial has a defined question

SURMOUNT-5 directly compared tirzepatide and semaglutide in adults with obesity without diabetes over 72 weeks. It was randomized and open-label, meaning participants knew their assignment. This is a useful direct weight-outcome comparison; it did not compare retatrutide or test human lifespan. Read the 2025 trial report.

Cross-trial comparisons remain less secure because participant groups, treatments, follow-up and analysis can differ. Even within one trial, average change is not a prediction for every participant. Check who was included and how missing results and unwanted effects were handled.

Approved and investigational status in Canada

Checked in November 2026: Health Canada’s Drug Product Database lists authorized finished semaglutide and tirzepatide products, including Wegovy and Mounjaro KwikPen. Each record concerns that finished drug product; it does not authorize a research vial with the same compound name.

Retatrutide appears as the study drug in a Canadian phase 3 clinical-trial record. A trial listing is evidence of an investigational programme, not market authorization. The phase 2 paper cited above remains a historical research example rather than a complete account of the programme’s current stage.

Does a triple agonist replace the need to read the trial?

No. Receptor terminology describes targets. The study establishes which outcomes were assessed in which people, over what period, and with what reported risks. Our research-reading guide explains how to check those details.

Compare metabolic trials fairly

Receptor targets explain a mechanism, while trial design determines which clinical comparisons can be made. Read the trial-comparison checklist before ranking outcomes across separate studies.

Explore this topic further

Retatrutide in Canada

The Peptide Place Insider

Your first order.
15% better.
Get 15% off
your first order.

Your welcome code, orders and Peptide Points. One free account.

Join Insider emails and create your free Peptide Place account. Unsubscribe anytime. Adults 19+.

Privacy · Offer terms · Already joined? Sign in